MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Free Cash flow
$7,260K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net income (loss)
    • Proceeds from stock option exerc...
    • Inventories
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable
    • Repayment of long-term debt
    • Other non-current assets and lia...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
11,578
1,554
1,483
-1,927
Stock-based compensation
1,468
1,518
1,124
1,092
Depreciation and amortization
1,386
1,131
1,017
1,009
Inventory step-up
650
350
1,421
1,324
Excess and obsolete inventory reserve
354
227
594
-
Debt discount amortization and non-cash interest expenses
160
118
175
179
Non-cash lease expense
36
9
9
5
Other operating activity
-
-7
-
-
Accounts receivable
11,478
1,651
-1,325
-1,371
Inventories
-3,319
-1,406
581
-5,614
Prepaid expenses and other assets
1,015
-1,754
2,521
122
Accounts payable
921
2,508
-3,284
2,122
Accrued medicaid rebates
-172
1,824
-8,714
1,806
Accrued liabilities
2,236
-1,532
426
1,786
Other non-current assets and liabilities
2,181
1,818
4,025
2,233
Acquisition of business
-
-
0
-
Net cash from operating activities
7,255
7,405
-11,551
12,026
Purchases of product license rights
0
15,000
0
0
Purchases of property and equipment
-5
75
49
284
Net cash used in investing activities
5
-15,075
-49
-284
Net proceeds from the issuance of long-term debt
-
-
0
-
Repayment of long-term debt
-
-
0
0
Common stock issued in private placement offering
-
-
0
-
Proceeds from stock option exercises
4,043
-
598
-
Payment of tax withholding related to net share settlement of stock option exercises
-
-
0
-
Proceeds from shares issued under the espp
-1,119
1,389
-177
0
Repayment of long-term debt
-3,000
-
-
-
Net cash from financing activities
-76
1,389
421
0
Change in cash and cash equivalents
7,184
-6,281
-11,179
11,742
Cash and cash equivalents at beginning of period
19,661
25,942
37,121
14,936
Cash and cash equivalents at end of period
26,845
19,661
25,942
37,121
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income (loss)$11,578K (378.52%↑ Y/Y)Purchases of property andequipment-$5K Inventories-$3,319K (-130.42%↓ Y/Y)Accrued liabilities$2,236K (286.18%↑ Y/Y)Stock-based compensation$1,468K (-55.46%↓ Y/Y)Depreciation andamortization$1,386K (-31.32%↓ Y/Y)Accounts payable$921K (-88.44%↓ Y/Y)Inventory step-up$650K (-72.33%↓ Y/Y)Excess and obsoleteinventory reserve$354K Debt discountamortization and non-cash...$160K (-53.22%↓ Y/Y)Non-cash lease expense$36K (20.00%↑ Y/Y)Net cash fromoperating activities$7,255K (-27.80%↓ Y/Y)Net cash used ininvesting activities$5K Canceled cashflow$14,846K Change in cash and cashequivalents$7,184K (-31.21%↓ Y/Y)Canceled cashflow$76K Accounts receivable$11,478K (26.24%↑ Y/Y)Other non-currentassets and liabilities$2,181K (123.27%↑ Y/Y)Prepaid expenses andother assets$1,015K (251.04%↑ Y/Y)Accrued medicaidrebates-$172K (-101.84%↓ Y/Y)Proceeds from stockoption exercises$4,043K Net cash fromfinancing activities-$76K (-119.29%↓ Y/Y)Canceled cashflow$4,043K Repayment of long-termdebt-$3,000K Proceeds from sharesissued under the espp-$1,119K (-384.01%↓ Y/Y)

Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals, Inc. (ETON)